In general, a weaker USD has a negative impact on Benelux stocks, particularly for companies with significant exports to the US. In this note we selected a list of companies with high US export exposure and we examine the potential impact on FY25 earninings. On top of the weak dollar, rising trade tensions or the introduction of tariffs further harm Benelux exporters. As the dollar depreciates against the euro, European goods become costlier for American consumers. At the same time, revenues ear...
UCB has announced plans to build a new state-of-the-art biologics manufacturing facility in the US, which today accounts for 55% of its revenues. The investment, estimated at $ 2bn over 6–7 years, is expected to generate a $ 5bn economic impact, including 300 permanent and > 500 construction jobs. This move aligns UCB with other major pharma players expanding US operations and may help mitigate risks from potential US import tariffs on pharmaceuticals. Additionally, UCB will strengthen its partn...
UCB and Biogen presented additional Phase 3 data showing that dapirolizumab pegol (DZP, anti-CD40L) significantly improves fatigue and disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE). Beyond the positive topline readout in Nov '24, DZP showed superior results over standard care in multiple fatigue and disease remission measures. Accumulate/€214 TP confirmed.
At EULAR 2025, UCB presented three-year data for Bimzelx, demonstrating sustained efficacy and inflammation control in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). In PsA, both biologic-naïve (53.2%) and TNFa-refractory patients (55.2%) maintained strong ACR50 responses and showed high rates of joint and skin symptom resolution. In axSpA, patients with both radiographic and non-radiographic forms sustained ASAS40 responses and low disease activity. These results highlight Bimze...
Colruyt: FY24/25F set to be in line with recently revised guidance. Exor: In search of a €2bn deal. Flow Traders: Sell In May And Go Away. Kinepolis: Peer Cineplex May 2025 box office revenue up 63% YoY, at 81% of 2019 level. Staffing: Dutch Period 5 - May vols up, strong pricing, working days/comps might distort. Staffing: French staffing - strong April data, May outlook also better
EVS Communicates the Results of the Extraordinary General Meeting of June 10, 2025 EVS COMMUNICATES THE RESULTS OF THE EXTRAORDINARY GENERAL MEETING OF JUNE 10, 2025 EVS Broadcast Equipment SA, leading provider of live video production systems, held a postponed Extraordinary General Meeting on Tuesday, June 10, 2025 (due to the lack of attendance quorum at the Extraordinary General Meeting convened on May 20, 2025). In total 163 shareholders representing 3,721,388 shares, or 25.97% of the company shares, attended (by proxy) the Extraordinary General Meeting held physically at the compan...
EVS COMMUNIQUE LES RESULTATS DE L’ASSEMBLEE GENERALE EXTRAORDINAIRE DU 10 JUIN 2025 EVS COMMUNIQUE LES RESULTATS DE L’ASSEMBLEE GENERALE EXTRAORDINAIRE DU 10 JUIN 2025 EVS Broadcast Equipment SA, leader des systèmes de production vidéo en direct, a tenu ce mardi 10 juin 2025 une Assemblée Générale Extraordinaire reportée (l’Assemblée Générale Extraordinaire convoquée le 20 mai 2025 n’ayant pas réuni le quorum de présence requis). Au total, 163 actionnaires représentant 3.721.388 titres, soit 25,97% du capital de la société, ont pris part (par procuration) à cette Assemblée qui s’est dér...
We initiate with a BUY due to our proprietary Contribution Analysis showing that the UCB EBITDA margin should explode by ~1500bps to ~45% by 2030. This leaves us 23% above consensus EBITDA. Interestingly, Cimzia is the biggest driver of our 5% above cons. 2030 sales as a result of our analysis showing that ~80% of TRx’s are women & this cohort is stable. We show that Bimzelx pricing could fall as much as 30% by 2030 due to rebates & mix but we are still in-line with consensus. There are still ma...
Ageas: Reinsurance partnership with TRIGLAV, taking QS on Italian motor direct insurance Belgian Telecoms: Digi introduces a new mobile subscription at €3. Kinepolis: Box office in US/Canada up 76% YoY while France visitors were down 25%. NN Group & ASR: Dutch coalition collapse not affecting Dutch Pension Reform. SBM Offshore: Farewell Aseng after 13.5 years of service. Events Calendar
In this June update, we've made four adjustments to the KBC Securities Dynamic Top Pick List: 1.Merus (Removed – 27 May) was removed following the release of strong interim Phase 2 data at the ASCO 2025 conference. Its lead asset, petosemtamab, in combination with Keytruda, showed a 63% overall response rate in first-line treatment of head and neck cancer—significantly outperforming Keytruda monotherapy. The resulting share price surge validated our investment thesis. 2. Adyen (Removed) has de...
Aedifica and Cofinimmo: Agreement reached to create Europe's leading Healthcare REIT. bpost: CMD press release; #Reshape 2029. D'Ieteren: Belgian new car registrations down 11.7% in May, VW down 13.5% Fugro: Meeting with CEO & IR; 2Q25 also has its challenges. UCB: Peer Moonlake held takeover talks with US Merck, FT reports
We updated our model after EVS highlighted 1Q25 was slightly below its own expectations, primarily due to the deferral of certain customer deliveries from March to April. EVS stressed that this timing-related impact does not alter their underlying business momentum. EVS indicated that customer demand remains robust across all regions. We welcome EVS remains cautiously optimistic about achieving its FY25 revenue objectives though, given the macro-economic tensions, the tariff discussions and the ...
EVS Invites Its Shareholders to a Postponed Extraordinary General Meeting on June 10, 2025 EVS INVITES ITS SHAREHOLDERS TO A POSTPONED EXTRAORDINARY GENERAL MEETING ON JUNE 10, 2025 As already communicated on May 20, 2025, due to the lack of attendance quorum, the Extraordinary General Meeting of EVS Broadcast Equipment SA convened on May 20, 2025 is postponed to June 10, 2025, at 12:00 pm, at its registered office in Liège, to deliberate on the agenda available on the website of the company (see link below). The Board of Directors will propose to this effect to the Shareholders to appr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.